2 Drug Stocks Climbing on FDA News

CRSP and KMDA stocks are attempting to take out resistance

Managing Editor
Apr 16, 2019 at 10:24 AM
facebook twitter linkedin

Two pharma names are scaling the Nasdaq this morning, thanks to favorable rulings from the Food and Drug Administration (FDA). First up is CRISPR Therapeutics AG (NASDAQ:CRSP), up 9.1% to trade at $40.52, after the FDA granted fast-track designation for CTX001 -- a treatment of transfusion-dependent beta thalassemia, a blood disorder -- made by CRISPR and Vertex Pharmaceuticals (VRTX). 

Thanks to a late-February bull gap, CRSP stock broke out of a channel of lower highs and lows that started last May. Today, the shares are attempting to end atop the $40 level -- an area that has served as resistance for the last month -- and their 200-day moving average, which would mark a feat not accomplished since September. CRSP has now added more than 30% in 2019.

A short squeeze could keep the wind at the equity's back. Short interest increased by 18.5% in the two most recent reporting periods, to a record high 5.26 million shares. This accounts for a healthy 17.6% of CRSP's total available float, and nearly two weeks' worth of pent-up buying power, at its average pace of trading. 

Then there's Kamada Ltd (NASDAQ:KMDA), up 8.5% to trade at $6.54, earlier tapping a nearly two-year high of $6.70. This morning, the company said it received a letter from the FDA stating it had satisfactorily addressed concerns regarding a study of its Inhaled Alpha-1-Antitrypsin to treat a genetic disorder. Kamada expects to initiate a late-stage trial in the second half of 2019.

This is pacing to be Kamada stock's best day since June 2017. KMDA shares have struggled to top the $6.25-$6.50 area since September, and were rejected here in late February. However, their subsequent pullback found support at their 200-day moving average. Today's news could prompt more analysts to take a look at Kamada stock. Only two brokerages are currently in coverage, doling out "buy" ratings and a $9 price target.


Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Schaeffer's Daily Bulletin Offer


Special Offers from Schaeffer's Trading Partners